161 related articles for article (PubMed ID: 37249823)
1. Economic Burden of Idiopathic Pulmonary Fibrosis in Spain: A Prospective Real-World Data Study (OASIS Study).
Rodríguez-Nieto MJ; Cano-Jiménez E; Romero Ortiz AD; Villar A; Morros M; Ramon A; Armengol S
Pharmacoeconomics; 2023 Aug; 41(8):999-1010. PubMed ID: 37249823
[TBL] [Abstract][Full Text] [Related]
2. Clinical management and acute exacerbations in patients with idiopathic pulmonary fibrosis in Spain: results from the OASIS study.
Cano-Jiménez E; Romero Ortiz AD; Villar A; Rodríguez-Nieto MJ; Ramon A; Armengol S
Respir Res; 2022 Sep; 23(1):235. PubMed ID: 36071483
[TBL] [Abstract][Full Text] [Related]
3. Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis.
Reichmann WM; Yu YF; Macaulay D; Wu EQ; Nathan SD
BMC Pulm Med; 2015 Dec; 15():167. PubMed ID: 26714746
[TBL] [Abstract][Full Text] [Related]
4. Hospital-Based Resource Use and Costs Among Patients With Idiopathic Pulmonary Fibrosis Enrolled in the Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry.
Fan Y; Bender SD; Conoscenti CS; Davidson-Ray L; Cowper PA; Palmer SM; de Andrade JA;
Chest; 2020 Jun; 157(6):1522-1530. PubMed ID: 32004554
[TBL] [Abstract][Full Text] [Related]
5. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial.
Behr J; Prasse A; Kreuter M; Johow J; Rabe KF; Bonella F; Bonnet R; Grohe C; Held M; Wilkens H; Hammerl P; Koschel D; Blaas S; Wirtz H; Ficker JH; Neumeister W; Schönfeld N; Claussen M; Kneidinger N; Frankenberger M; Hummler S; Kahn N; Tello S; Freise J; Welte T; Neuser P; Günther A;
Lancet Respir Med; 2021 May; 9(5):476-486. PubMed ID: 33798455
[TBL] [Abstract][Full Text] [Related]
6. Clinical course of IPF in Italian patients during 12 months of observation: results from the FIBRONET observational study.
Poletti V; Vancheri C; Albera C; Harari S; Pesci A; Metella RR; Campolo B; Crespi G; Rizzoli S;
Respir Res; 2021 Feb; 22(1):66. PubMed ID: 33627105
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of forced vital capacity decline prior to and following antifibrotic therapy in idiopathic pulmonary fibrosis.
Aono Y; Nakamura Y; Kono M; Nakamura H; Yokomura K; Imokawa S; Toyoshima M; Yasui H; Hozumi H; Karayama M; Suzuki Y; Furuhashi K; Enomoto N; Fujisawa T; Inui N; Suda T
Ther Adv Respir Dis; 2020; 14():1753466620953783. PubMed ID: 32928050
[TBL] [Abstract][Full Text] [Related]
8. Treatment patterns, resource use and costs of idiopathic pulmonary fibrosis in Spain--results of a Delphi Panel.
Morell F; Esser D; Lim J; Stowasser S; Villacampa A; Nieves D; Brosa M
BMC Pulm Med; 2016 Jan; 16():7. PubMed ID: 26758510
[TBL] [Abstract][Full Text] [Related]
9. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
Feng H; Zhao Y; Li Z; Kang J
Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705
[TBL] [Abstract][Full Text] [Related]
10. Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry.
Behr J; Prasse A; Wirtz H; Koschel D; Pittrow D; Held M; Klotsche J; Andreas S; Claussen M; Grohé C; Wilkens H; Hagmeyer L; Skowasch D; Meyer JF; Kirschner J; Gläser S; Kahn N; Welte T; Neurohr C; Schwaiblmair M; Bahmer T; Oqueka T; Frankenberger M; Kreuter M
Eur Respir J; 2020 Aug; 56(2):. PubMed ID: 32381492
[TBL] [Abstract][Full Text] [Related]
11. Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis.
Paterniti MO; Bi Y; Rekić D; Wang Y; Karimi-Shah BA; Chowdhury BA
Ann Am Thorac Soc; 2017 Sep; 14(9):1395-1402. PubMed ID: 28388260
[TBL] [Abstract][Full Text] [Related]
12. Real world experience of response to pirfenidone in patients with idiopathic pulmonary fibrosis: a two centre retrospective study.
Eaden JA; Barber CM; Renshaw SA; Chaudhuri N; Bianchi SM
Sarcoidosis Vasc Diffuse Lung Dis; 2020; 37(2):218-224. PubMed ID: 33093786
[TBL] [Abstract][Full Text] [Related]
13. Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial.
Raghu G; van den Blink B; Hamblin MJ; Brown AW; Golden JA; Ho LA; Wijsenbeek MS; Vasakova M; Pesci A; Antin-Ozerkis DE; Meyer KC; Kreuter M; Santin-Janin H; Mulder GJ; Bartholmai B; Gupta R; Richeldi L
JAMA; 2018 Jun; 319(22):2299-2307. PubMed ID: 29800034
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal clinical outcomes in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry.
Wuyts WA; Dahlqvist C; Slabbynck H; Schlesser M; Gusbin N; Compere C; Maddens S; Lee YC; Kirchgaessler KU; Bartley K; Bondue B
Respir Res; 2019 Oct; 20(1):231. PubMed ID: 31651324
[TBL] [Abstract][Full Text] [Related]
15. Real-World Study Analysing Progression and Survival of Patients with Idiopathic Pulmonary Fibrosis with Preserved Lung Function on Antifibrotic Treatment.
Noor S; Nawaz S; Chaudhuri N
Adv Ther; 2021 Jan; 38(1):268-277. PubMed ID: 33098554
[TBL] [Abstract][Full Text] [Related]
16. Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trials.
Kreuter M; Wuyts WA; Wijsenbeek M; Bajwah S; Maher TM; Stowasser S; Male N; Stansen W; Schoof N; Orsatti L; Swigris J
Respir Res; 2020 Jan; 21(1):36. PubMed ID: 32000772
[TBL] [Abstract][Full Text] [Related]
17. The economic burden of idiopathic pulmonary fibrosis in Australia: a cost of illness study.
Cox IA; de Graaff B; Ahmed H; Campbell J; Otahal P; Corte TJ; Moodley Y; Goh N; Hopkins P; Macansh S; Walters EH; Palmer AJ
Eur J Health Econ; 2023 Sep; 24(7):1121-1139. PubMed ID: 36289130
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and safety of mycophenolate mofetil in idiopathic pulmonary fibrosis.
Nambiar AM; Anzueto AR; Peters JI
PLoS One; 2017; 12(4):e0176312. PubMed ID: 28441449
[TBL] [Abstract][Full Text] [Related]
19. Lung function trajectories in patients with idiopathic pulmonary fibrosis.
Neely ML; Hellkamp AS; Bender S; Todd JL; Liesching T; Luckhardt TR; Oldham JM; Raj R; White ES; Palmer SM
Respir Res; 2023 Aug; 24(1):209. PubMed ID: 37612608
[TBL] [Abstract][Full Text] [Related]
20. Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study.
Raghu G; van den Blink B; Hamblin MJ; Brown AW; Golden JA; Ho LA; Wijsenbeek MS; Vasakova M; Pesci A; Antin-Ozerkis DE; Meyer KC; Kreuter M; Moran D; Santin-Janin H; Aubin F; Mulder GJ; Gupta R; Richeldi L
Lancet Respir Med; 2019 Aug; 7(8):657-664. PubMed ID: 31122893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
